The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sazhin A.V.

Pirogov Russian National Research Medical University

Khusyainova A.I.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Petukhov V.A.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Surgical management of diabetes mellitus: future outlook

Authors:

Sazhin A.V., Khusyainova A.I., Petukhov V.A.

More about the authors

Journal: Endoscopic Surgery. 2017;23(1): 46‑55

DOI: 10.17116/endoskop201723146-55

Views: 4642

Downloaded: 59

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Sazhin AV, Khusyainova AI, Petukhov VA. Surgical management of diabetes mellitus: future outlook. Endoscopic Surgery. 2017;23(1):46‑55. (In Russ.)
https://doi.org/10.17116/endoskop201723146-55

Подписка 2025 (Endoscopic Surgery)
МСФ на ЯМ
Close metadata

Keywords:

diabetes mellitus type 2
bile acids
maldigestion syndrome
microflora
surgical management of diabetes mellitus

Authors:

Sazhin A.V.

Pirogov Russian National Research Medical University

Khusyainova A.I.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

Petukhov V.A.

Department of faculty surgery named after S.I. Spasokukotskyi, School of general medicine, Pirogov Russian National Research Medical University, Moscow, Russia

List of references:

  1. Dedov II, Shestakova MV, Vikulova OK. The State Register of diabetes in the Russian Federation: 2014 status and development prospects. Diabetes. 2015;18(3):5-23. (In Russ.)
  2. William T, Petersen M, Ratner R. The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action! Diabetes Care. 2014 Dec;37(12):3137-3138.
  3. Herman W. The economic costs of diabetes: is it time for a new treatment paradigm? Diabetes Care. 2013 Apr; 36(4):775-776. https://doi.org/10.2337/dc13-0270
  4. Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D. Expression and function of the bile acid re-ceptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008 Jul;18;372(1):78-84. https://doi.org/10.1016/j.bbrc.2008.04.171
  5. Rubino F, Nathan D, Eckel R, Schauer P, George K, Alberti M, Zimmet P, Del Prato S, Ji L, Sadikot S, Herman W, Amiel S, Kaplan L, Taroncher-Oldenburg G, Cummings D. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations on behalf of the Delegates of the 2nd Diabetes Surgery Summit. Diabetes Care. 2016 Jun;39(6):861-877. https://doi.org/10.2337/dc16-0236
  6. Buchwald H. Lowering of cholesterol absorbtion and blood levels by ileal exclusion. Circulation. 1964;29:713-720.
  7. Buchwald H, Richard B, Richard L. Surgical treatment of hyperlipidemia. Circulation. 1974;49(suppl. 1):65.
  8. Buchwald H, Moore R, Matts J. The programm on the surgical controle of the hyperlipidemias: a status report. Surgery. 1982;92(4):654-662.
  9. Buchwald H, Varco R, Matts J, Long J, Fitch L, Campbell G, Pearce M, Yellin A, Edmiston W, Smink RJr. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990 Oct 4;323(14):946-955.
  10. Lebedev LV, Sedletskii YuI. Surgical treatment of obesity and hyperlipidemia. L.: Medicine. 1987;215. (In Russ.).
  11. Savelyev VS, Yablokov EG, Petukhov VA. Buchwald operation in surgery obliterative sclerosis. Thoracic and Cardiovascular Surgery. 1992:11-12:41-43. (In Russ.).
  12. epub ahead of print. https://doi.org/10.1016/j.soard.2016.01.025
  13. About diabetes. World Health Organization. Retrieved 4. April 2014.
  14. Tkachuk VA, Vorotnikov AV. Molecular mechanisms of resistance to insulin. Sugar diabet. 2014;2:29-41. (In Russ.) https://doi.org/10.14341/DM20142
  15. Isganaitis E. Lustig R. Fast Food, Central Nervous System Insulin Resistance, and Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(12):2451-2462. https://doi.org/10.1161/01.ATV.0000186208.06964.91
  16. Yudkin J, Richter B, Gale E. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010 Oct;53(10):2079-2085. https://doi.org/10.1007/s00125-010-1864-z
  17. Keitel V, Cupisti K, Ullmer C, Knoefel W, Kubitz R, Häussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology. 2009;50:861-870. https://doi.org/10.1002/hep.23032
  18. Bower G, Toma T, Harling L, Jiao L, Efthimiou E, Darzi A. Bariatric surgery and Non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015. https://doi.org/10.1007/s11695-015-1691-x
  19. Levit Sh, Filippov YuI, Gorelyshev AS. Type 2 Diabetes: time to change the concept. Diabetes. 2013;1(58):91-102. (In Russ.) https://doi.org/10.14341/DM2014187-88
  20. Parfenov AI. Maldigestion Syndrome. Experimental and clinical gastroenterology. 2008;7:67-81. (In Russ.)
  21. Machov VM, Melnichenko GA, Budennaya IYu, Volodina VT, Glinkina IV, Zilov AV. Diabetic gastroparesis. BC. 2014;15:11-33. (In Russ.)
  22. Kong M, Horowitz M, Jones K. Natural History of Diabetic Gastroparesis. Diabetes Care. 1999;22:503-507.
  23. Sirotin BZ, Fedorchenko YuL, Vit’ko LG, Marenin SN. Diabetes and esophageal pathology. Clinical prospects of gastroenterology, hepatology. 2009;6:22-25. (In Russ.)
  24. Jung H, Choung R, Locke G, Schleck C, Zinsmeister A. Szarka L, Mullan B, Talley N. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009 Apr;136(4):1225-1233. https://doi.org/10.1053/j.gastro.2008.12.04
  25. Papasavas P, Ng J, Stone A, Ajayi O, Muddasani K, Tishler D. Gastric bypass surgery as treatment of recalcitrant gastroparesis. Surg Obes Relat Dis. 2014 Sep-Oct;10(5):795-799. https://doi.org/10.1016/j.soard.2014.01.013
  26. Hazlehurst J, Woods C, Marjot T, Cobbold J, Tomlinson J. Non-alcoholic fatty liver disease and diabetes. Metabolism. 2016 Aug;65(8):1096-1108. https://doi.org/10.1016/j.metabol.2016.01.001
  27. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-1218. https://doi.org/10.2337/dc06-2247
  28. Williamson R, Price J, Glancy S, Perry E, Nee L, Hayes P. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-1144. https://doi.org/10.2337/dc10-2229
  29. Feldman M, Feldman MJr. The incidence of cholelithiasis, cholesterolosis and liver disease in diabetes mellitus: an autopsy study. Diabetes. 1954;3;305-307.
  30. Shibat M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30:2940-2944. https://doi.org/10.2337/dc07-0792. Gastroenterol. 2010;105:2389-2395.
  31. Bae J, Rhee E, Lee W, Park S, Park C, Oh K. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34:727-729.
  32. Marco D, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756-761.
  33. Courcoulas A, Belle S, Neiberg R, Pierson S, Eagleton J, Kalarchian M. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. Jama Surg. 2015. https://doi.org/10.1001/jamasurg.2015.1534
  34. Savelyev VS, Petuhov VA. Lipid distress syndrome. M: MAKS Press. 2010;659. (In Russ.)
  35. Savelyev VS, Petukhov VA, Bol’din BV. Cholesterosis gallbladder. M.: Vedi. 2002;175. (In Russ.)
  36. Keitel V, Donner M, Winandy S, Kubitz R, Häussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008 Jul;18;372(1):78-84. https://doi.org/10.1016/j.bbrc.2008.04.171
  37. Lavoie B, Balemba O, Godfrey C, Watson C, Vassileva G, Corvera C, Nelson M, Mawe G. Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. Journal of Physiology. 2010;588:3295-3305. https://doi.org/10.1113/jphysiol.2010.192146
  38. Knop F. Bile-induced secretion of glucagon-like peptide-1: Pathophysiological implications in type 2 diabetes? American Journal of Physiology - Endocrinology and Metabolism Published. 2010 27 April. https://doi.org/10.1152/ajpendo.00137.2010
  39. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor 308 for bile acids (M-BAR). Biochem Biophys Res Commun. 2002;298:714-719.
  40. Watanabe M, Houten S, Mataki C, Christoffolete M, Kim B, Sato H, Messaddeq N, Harney J, Ezaki O, Kodama T, Schoonjans K, Bianco A, Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid 380 hormone activation. Nature. 2006;4439:484-489.
  41. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T, Shintani Y. A G protein-coupled receptor responsive to bile acids. Journal of Biological Chemistry. 2003;278:9435-9440. https://doi.org/10.1074/jbc.M209706200
  42. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochemical and Biophysical Research Communications. 2005;329:386-390. https://doi.org/10.1016/j.bbrc.2005.01.139
  43. Adrian T, Gariballa S, Parekh K, Thomas S, Saadi H, AlKaabi J, Nagelkerke N, Gedulin B, Young A. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia. 2012;55:2343-2347. https://doi.org/10.1007/s00125-012-2593-2
  44. Garg A, Grundy S. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Annals of Internal Medicine. 1994;121:416-422. https://doi.org/10.7326/0003-4819-121-6-199409150-00004
  45. Zieve F, Kalin M, Jones M, Bailey W. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clinical Therapeutics. 2007;29:74-83. https://doi.org/10.1016/j.clinthera.2007.01.003
  46. Jain A, Stoll B, Burrin D, Holst J, Moore D. Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2012;302:G218-G224. https://doi.org/10.1152/ajpgi.00280.2011
  47. Roberts R, Glicksman C, Alaghband-Zadeh J, Sherwood R, Akuji N, le Roux C. The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. Clinical Endocrinology. 2011;74:67-72. https://doi.org/10.1111/j.1365-2265.2010.03886.x
  48. Ballantyne G. Peptide YY (1—36) and peptide YY(3—36): Part I. Distribution, release and actions. Obesity Surgery. 2006;16:651-658. https://doi.org/10.1381/096089206776944959
  49. Holst J. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87:1409-1439. https://doi.org/10.1152/physrev.00034.2006
  50. Thoms C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A,Yamamoto H, Mataki C, Pruzanski M. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metabolism. 2009;10:167-177. https://doi.org/10.1016/j.cmet.2009.08.001
  51. Burhol P, Lygren I, Waldum H, Jorde R. The effect of duodenal infusion of bile on plasma VIP, GIP, and secretin and on duodenal bicarbonate secretion. Scandinavian Journal of Gasteroenterology. 1980;15:1007-1011. https://doi.org/10.3109/00365528009181805
  52. Flaten O, Hanssen L, Osnes M, Myren J. Plasma concentrations of gastric inhibitory polypeptide after intraduodenal infusion of cattle bile and synthetic bile salts in man. Scandinavian Journal of Gasteroenterology. 1981;16:1073-1075. https://doi.org/10.3109/00365528109181031
  53. Lefebvre P, Cariou B, Lien F, Kuipers F. Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiological Reviews. 2009;89:147-191. https://doi.org/10.1152/physrev.00010.2008
  54. Trauner M, Boyer J. Bile salt transporters: molecular characterization, function, and regulation. Physiological Reviews. 2003;83:633-671. https://doi.org/10.1152/physrev.00027.2002
  55. Hofmann A. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metabolism Reviews. 2004;36:703-722. https://doi.org/10.1081/DMR-200033475
  56. Makishima M, Lu T, Xie W, Whitfield G, Domoto H, Evans R,Haussler M, Mangelsdorf D. Vitamin D receptor as an intestinal bile acid sensor. Scienc. 2002;296:1313-1316. https://doi.org/10.1126/science.1070477
  57. Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, Bouchaert E, Briand O, Brozek J, Kuipers F, Fievet C, Cariou B, Staels B. The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem. 2010 Nov 19;285(47):36759-36767. https://doi.org/10.1074/jbc.M110.166231
  58. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep. 2011 Jun;11(3):160-166. https://doi.org/ 10.1007/s11892-011-0187-x
  59. Brufau G, Bahr M, Staels B, Claudel T, Ockenga J, Böker K, Murphy E, Prado K. Stellaard F, Manns M, Kuipers F, Tietge U. Plasma bile acids are not associated with energy metabolism in humans. Nutr Metab (Lond). 2010 Sep 3;7:73. https://doi.org/10.1186/1743-7075-7-73
  60. Kohli R, Kirby M, Setchell K, Jha P, Klustaitis K, Woollett L, Pfluger P, Balistreri W, Tso P, Jandacek R, Woods S, Heubi J, Tschoep M, D’Alessio D, Shroyer N, Seeley R. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol. 2010 Sep;299(3):G652-G660. https://doi.org/10.1152/ajpgi.00221.2010
  61. Brufau G, Stellaard F, Prado K, Bloks V, Jonkers E, Boverhof R, Kuipers F, Murphy E. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology. 2010;52:1455-1464. https://doi.org/10.1002/hep.23831
  62. Prawitt J, Staels B. Bile acid sequestrants: glucose-lowering mechanisms. Metab Syndr Relat Disord. 2010 Dec;8(1):S3-S8. https://doi.org/10.1089/met.2010.0096
  63. Schwartz S, Lai Y, Xu J, Abby S, Misir S, Jones M, Nagendran S. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010 Apr;8(2):179-188. https://doi.org/10.1089/met.2009.0049
  64. Kobayashi M, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, Babaya N, Itoi-Babaya M, Yamaji K, Hiromine Y, Shibata M, Ogihara T. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes. 2007 Jan;56(1):239-247.
  65. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun. 2002 Nov 15;298(5):714-719.
  66. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008 Aug;7(8):678-693. https://doi.org/10.1038/nrd2619
  67. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009 Sep;10(3):167-177. https://doi.org/10.1016/j.cmet.2009.08.001
  68. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith R, Görgün C, Hotamisligil G. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006 Aug;25:313(5790):1137-1140.
  69. Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2020-2030. https://doi.org/10.1161/01.ATV.0000178994.21828.a7
  70. Toft-Nielsen M, Damholt M, Madsbad S, Hilsted L, Hughes T, Michelsen B, Holst J. Determinants of the impaired secretion of glucagon-like peptide-1 364 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723.
  71. Palasciano G, Portincasa P, Belfiore A, Baldassarre G, Albano O. Opposite effects of cholestyramine and loxiglumide on gallbladder dynamics in humans. Gastroenterology. 1992;102:633-639.
  72. De Santis A, Attili A, Ginanni C, Scafato E, Cantagalli A, De L, Pinto G, Lisi D, Capocaccia L. Gallstones and diabetes: a case-control study in a free-248 living population sample. Hepatology. 1997;25:787-790.
  73. Sonne D, Rehfeld J, Holst J, Vilsbøll T, Knop F. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. Eur J Endocrinol. 2014 Oct;171(4):407-419. https://doi.org/10.1530/EJE-14-0309
  74. Zarrinpar A, Loomba R. Systematic Review: The emerging interplay between bile acids, gastrointestinal tract, and incretins in the pathogenesis of diabetes and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2012 Nov;36(10):909921. https://doi.org/10.1111/apt.12084
  75. Bergman R, Prager R, Volund A, Olefsky J. Equivalence of the insulin sensitivity index in man derived by the minimal model method and euglycaemic glucose clamp. J Clin Invest. 1987;79:790-800.
  76. Fasano A. Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin. Ann N Y Acad Sci. 2000;915:214-222.
  77. Buchan A, Polak J, Capella C, Solcia E, Pearse A. Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 1978;56:37-44.
  78. Eissele R, Goke R, Willemer S. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992;22:283-291.
  79. Parks D, Blanchard S, Bledsoe R. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365-1368.
  80. Holt J, Luo G, Billin A. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003;17:1581-1591.
  81. Vilsboll T, Krarup T, Madsbad S, Holst J. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept. 2003;114:115-121.
  82. Staels B, Fonseca V. Bile acids and metabolic regulation. Diabetes Care. 200;3:S237-S245. https://doi.org/10.2337/dc09-S355
  83. Knop F. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes. Am J Physiol Endocrinol Metab. 2010;299:E10-E13.
  84. Savelyev VS, Yablokov EG, Petukhov VA. The results of surgery in the treatment of partial ileoshuntirovaniya dyslipidemia. Annals of Surgery. 1999;3:16-20. (In Russ.)
  85. Savelyev VS, Petuhov VA. A new method for the treatment of disorders of the liver function in type 2 diabetes and diabetic angiopathy. Difficult patient. 2004;2:5:24-30.(In Russ.)
  86. Hofmann A. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology. 2011 May;53(5):1784. https://doi.org/10.1002/hep.24100
  87. Staels B. Review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus. Postgrad med. 2009 May;121(3 suppl 1):25-30. https://doi.org/10.3810/pgm.2009.05.suppl53.290
  88. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier A, Gérard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12):1787-1794. https://doi.org/10.1136/gutjnl-2012-303816
  89. Abdul-Hai A, Abdallah A, Malnick S. Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World J Hepatol. 2015 Jun; 28;7(12):1679-1684. https://doi.org/10.4254/wjh.v7.i12.1679
  90. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, Nakamura T, Itadani H, Tanaka K. Identification of membrane-type receptor for bile acids (M-BAR). Biochemical and Biophysical Research Communications. 2002;298:714-719. https://doi.org/10.1016/S0006-291X(02)02550-0
  91. Keitel V, Reinehr R, Rupprecht C, Görg B,Selbach O, Häussinger D, Kubitz R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007;45:695-704. https://doi.org/10.1002/hep.21458
  92. Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart J-C, Kuipers F, Staels B. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes. 2004;53:890-898. https://doi.org/10.2337/diabetes.53.4.890
  93. Bennion L, Grundy S. Effects of diabetes mellitus on cholesterol metabolism in man. New England Journal of Medicine. 1977;296:1365-1371. https://doi.org/10.1056/NEJM197706162962401
  94. Cani P, Delzenne N. The role of the gut microbiota in energy metabolism and metabolic disease. Current Pharmaceutical Design. 2009;15:1546-1558. https://doi.org/10.2174/138161209788168164
  95. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55-60. https://doi.org/10.1038/nature11450
  96. Odunsi-Shiyanbade S, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio I, Lamsam J, Singh R, Zinsmeister A. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clinical Gastroenterology and Hepatology. 2010;8:159-165.e5. https://doi.org/10.1016/j.cgh.2009.10.020
  97. Rosenstock J, Hernandez-Triana E, Handelsman Y, Misir S, Jones M. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgraduate Medicine. 2012;124:14-20. https://doi.org/10.3810/pgm.2012.07.2564
  98. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, Häring H-U, Schleicher E, Xu G, Lehmann R. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? American Journal of Physiology. Endocrinology and Metabolism. 2009;296:E384-E393. https://doi.org/10.1152/ajpendo.90748.2008
  99. Donovan J, Von Bergmann K, Setchell K, Isaacsohn J, Pappu A, Illingworth D, Olson T, Burke S. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Digestive Diseases and Sciences. 2005;50:1232-1238. https://doi.org/10.1007/s10620-005-2765-8
  100. Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. Southern Medical Journal. 2006;99:257-273. https://doi.org/10.1097/01.smj.0000208120.73327.db
  101. Shen H, Zhang Y, Ding H, Wang X, Chen L, Jiang H, Shen X. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cellular Physiology and Biochemistry. 2008;22:1-14. https://doi.org/10.1159/000149779
  102. Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. Journal of Biological Chemistry. 2003;278:39124-39132. https://doi.org/10.1074/jbc.M305079200
  103. Ma K, Saha P, Chan L, Moore D. Farnesoid X receptor is essential for normal glucose homeostasis. Journal of Clinical Investigation. 2006;116:1102-1109. https://doi.org/10.1172/JCI25604
  104. Portincasa P, Peeters T, van Berge-Henegouwen G, van Solinge W, Palas-ciano G, van Erpecum K. Acute intraduodenal bile salt depletion leads to strong gallbladder contraction, altered antroduodenal motility and high plasma motilin levels in humans. Neurogastroenterology and Motility. 2000;12:421-430. https://doi.org/10.1046/j.1365-2982.2000.00217.x
  105. Angelin B, Larsson T, Rudling M. Circulating fibroblast growth factors as metabolic regulators — a critical appraisal. Cell Metabolism. 2012;16:693-705. https://doi.org/10.1016/j.cmet.2012.11.001
  106. Zweers S, Booij K, Komuta M, Roskams T, Gouma D, Jansen P, Schaap F. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology. 2012;55:575-583. https://doi.org/10.1002/hep.24702
  107. Potthoff M, Boney-Montoya J, Choi M, He T, Sunny N, Satapati S, Suino-Powell K, Xu H, Gerard R, Finck B. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metabolism. 2011;13:729-738. https://doi.org/10.1016/j.cmet.2011.03.019
  108. Barutcuoglu B, Basol G, Cakir Y, Cetinkalp S, Parildar Z, Kabaroglu C, Ozmen D, Mutaf I, Bayindir O. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Annals of Clinical and Laboratory Science. 2011;41:390-396.
  109. Stejskal D, Karpísek M, Hanulová Z, Stejskal P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scandinavian Journal of Clinical and Laboratory Investigation. 2008;68:501-507. https://doi.org/10.1080/00365510701854967
  110. Jansen P, van Werven J, Aarts E, Berends F, Janssen I, Stoker J, Schaap F. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Digestive Diseases. 2011;29:48-51. https://doi.org/10.1159/000324128
  111. Patti M, Houten S, Bianco A, Bernier R, Larsen P, Holst J, Badman M, Maratos-Flier E, Mun E, Pihlajamaki J, Auwerx J, Goldfine A. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring). 2009 Sep;17(9):1671-1677. https://doi.org/10.1038/oby.2009.102
  112. Raghow R. Ménage-à-trois of bariatric surgery, bile acids and the gut microbiome. World J Diabetes. 2015 Apr;15;6(3):367-370. https://doi.org/10.4239/wjd.v6.i3.367
  113. Penney N, Kinross J, Newton R, Purkayastha S. The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. International Journal of Obesity. 2015;39:1565-1574. https://doi.org/10.1038/ijo.2015.115

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.